A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy

Thomas Klopstock, Patrick Yu-Wai-Man, Konstantinos Dimitriadis, Jacinthe Rouleau, Suzette Heck, Maura Bailie, Alaa Atawan, Sandip Chattopadhyay, Marion Schubert, Aylin Garip, Marcus Kernt, Diana Petraki, Christian Rummey, Mika Leinonen, Günther Metz, Philip G Griffiths, Thomas Meier, Patrick F Chinnery, Thomas Klopstock, Patrick Yu-Wai-Man, Konstantinos Dimitriadis, Jacinthe Rouleau, Suzette Heck, Maura Bailie, Alaa Atawan, Sandip Chattopadhyay, Marion Schubert, Aylin Garip, Marcus Kernt, Diana Petraki, Christian Rummey, Mika Leinonen, Günther Metz, Philip G Griffiths, Thomas Meier, Patrick F Chinnery

Abstract

Major advances in understanding the pathogenesis of inherited metabolic disease caused by mitochondrial DNA mutations have yet to translate into treatments of proven efficacy. Leber's hereditary optic neuropathy is the most common mitochondrial DNA disorder causing irreversible blindness in young adult life. Anecdotal reports support the use of idebenone in Leber's hereditary optic neuropathy, but this has not been evaluated in a randomized controlled trial. We conducted a 24-week multi-centre double-blind, randomized, placebo-controlled trial in 85 patients with Leber's hereditary optic neuropathy due to m.3460G>A, m.11778G>A, and m.14484T>C or mitochondrial DNA mutations. The active drug was idebenone 900 mg/day. The primary end-point was the best recovery in visual acuity. The main secondary end-point was the change in best visual acuity. Other secondary end-points were changes in visual acuity of the best eye at baseline and changes in visual acuity for both eyes in each patient. Colour-contrast sensitivity and retinal nerve fibre layer thickness were measured in subgroups. Idebenone was safe and well tolerated. The primary end-point did not reach statistical significance in the intention to treat population. However, post hoc interaction analysis showed a different response to idebenone in patients with discordant visual acuities at baseline; in these patients, all secondary end-points were significantly different between the idebenone and placebo groups. This first randomized controlled trial in the mitochondrial disorder, Leber's hereditary optic neuropathy, provides evidence that patients with discordant visual acuities are the most likely to benefit from idebenone treatment, which is safe and well tolerated.

Figures

Figure 1
Figure 1
(A) Visual acuity efficacy end-points (filled arrows) between baseline and Week 24. (1) Primary end-point—best recovery/least worsening in visual acuity, one value per patient. (2) Main secondary end-point—change in best visual acuity, one value per patient. (3) Pre-specified secondary end-point—change in visual acuity of best eye at baseline, one value per patient. (4) Pre-specified secondary end-point—change in visual acuity of all eyes (both eyes of a patient considered independent), two values per patient. (B) Visual acuity at baseline for all patients. Both eyes are shown for each subject, connected by a solid line (grey squares = eye with better visual acuity; black squares = eye with worse visual acuity). BL = baseline; CF = finger counting; HM = hand motion; LP = light perception; VA = visual acuity.
Figure 2
Figure 2
Change in visual acuity (logMAR) end-points over time for the change in best recovery of visual acuity (A and B), change in best visual acuity (C and D), change in visual acuity of the patients’ best eye at baseline (E and F) and change in visual acuity for all eyes (G and H). For each analysis two populations are presented: the whole study population (n = 82, intent-to-treat population for visual acuity end-points) (A, C, E and G) and subpopulation of patients with discordant visual acuities at baseline (n = 30, B, D, F and H). Filled squares/solid line = idebenone group; filled circles/dashed lines = placebo group, P-values for comparison between idebenone and placebo groups. Data are estimated means (±SEM) from mixed model for repeat measures based on the change from baseline. ITT = intent-to-treat; VA = visual acuity; W = weeks.
Figure 3
Figure 3
Change in colour contrast sensitivity for red–green (Protan; A) and blue–yellow (Tritan; B). Data are estimated mean changes from baseline (± SEM) from mixed model for repeat measures. Filled squares/solid lines = idebenone group; filled circles/dashed lines = placebo group.
Figure 4
Figure 4
Retinal nerve fibre layer thickness at baseline for patients with disease onset of ≤6, 6–12 and >12 months (A). The mean retinal nerve fibre layer thickness for the temporal, superior, nasal and inferior retinal quadrants are shown. Relative change from baseline to Weeks 4, 12 and 24 in retinal nerve fibre layer thickness (B). n = 6/4 (idebenone/placebo) for eyes with disease onset of ≤6 months; n = 8/6 for eyes with disease onset of 6–12 months; n = 32/26 for eyes with disease onset of >12 months. Filled squares/solid line = idebenone group; filled circles/dashed line = placebo group. RNFLT = retinal nerve fibre layer thickness.

References

    1. Arden GB, Wolf JE. Colour vision testing as an aid to diagnosis and management of age related maculopathy. Br J Ophthalmol. 2004;88:1180–5.
    1. Baracca A, Solaini G, Sgarbi G, Lenaz G, Baruzzi A, Schapira AH, et al. Severe impairment of complex I-driven adenosine triphosphate synthesis in leber hereditary optic neuropathy cybrids. Arch Neurol. 2005;62:730–6.
    1. Barboni P, Savini G, Valentino ML, Montagna P, Cortelli P, De Negri AM, et al. Retinal nerve fiber layer evaluation by optical coherence tomography in Leber's hereditary optic neuropathy. Ophthalmology. 2005;112:120–6.
    1. Barnils N, Mesa E, Munoz S, Ferrer-Artola A, Arruga J. Response to idebenone and multivitamin therapy in Leber's hereditary optic neuropathy. Arch Soc Esp Oftalmol. 2007;82:377–80.
    1. Carelli V, Barboni P, Zacchini A, Mancini R, Monari L, Cevoli S, et al. Leber's Hereditary Optic Neuropathy (LHON) with 14484/ND6 mutation in a North African patient. J Neurol Sci. 1998;160:183–8.
    1. Carelli V, Valentino ML, Liguori R, Meletti S, Vetrugno R, Provini F, et al. Leber's hereditary optic neuropathy (LHON/11778) with myoclonus: report of two cases. J Neurol Neurosurg Psychiatry. 2001;71:813–6.
    1. Cortelli P, Montagna P, Pierangeli G, Lodi R, Barboni P, Liguori R, et al. Clinical and brain bioenergetics imporvement with idebenone in a patient with Leber's hereditary optic neuropathy: a clinical and 31P-MRS study. J Neurol Sci. 1997;148:25–31.
    1. Grigsby SS, Vingrys AJ, Benes SC, King-Smith PE. Correlation of chromatic, spatial, and temporal sensitivity in optic nerve disease. Invest Ophthalmol Vis Sci. 1991;32:3252–62.
    1. Guy W. Clinical global impression. In: Guy W, editor. Assessment manual for psychopharmacology. Rockville, MD: US Department of Health, Education and Welfare; 1976. pp. 125–6.
    1. Haefeli RH, Erb M, Gemperli AC, Robay D, Courdier Fruh I, Anklin C, et al. NQO1-Dependent redox cycling of idebenone: effects on cellular redox potential and energy levels. PLoS One. 2011;6:e17963.
    1. Harding AE, Sweeney MG, Govan GG, Riordan-Eva P. Pedigree analysis in Leber hereditary optic neuropathy families with a pathogenic mtDNA mutation. Am J Hum Genet. 1995;57:77–86.
    1. Kirkman MA, Korsten A, Leonhardt M, Dimitriadis K, De Coo IF, Klopstock T, et al. Quality of life in patients with leber hereditary optic neuropathy. Invest Ophthalmol Vis Sci. 2009;50:3112–5.
    1. Lange C, Feltgen N, Junker B, Schulze-Bonsel K, Bach M. Resolving the clinical acuity categories "hand motion" and "counting fingers" using the Freiburg Visual Acuity Test (FrACT) Graefes Arch Clin Exp Ophthalmol. 2009;247:137–42.
    1. Man PY, Griffiths PG, Brown DT, Howell N, Turnbull DM, Chinnery PF. The epidemiology of leber hereditary optic neuropathy in the north East of England. Am J Hum Genet. 2003;72:333–9.
    1. Mashima Y, Hiida Y, Oguchi Y. Remission of Leber's hereditary optic neuropathy with idebenone. Lancet. 1992;340:368–9.
    1. Mashima Y, Kigasawa K, Wakakura M, Oguchi Y. Do idebenone and vitamin therapy shorten the time to achieve visual recovery in Leber hereditary optic neuropathy? J Neuroophthalmol. 2000;20:166–170.
    1. Newman NJ, Biousse V, David R, Bhatti MT, Hamilton SR, Farris BK, et al. Prophylaxis for second eye involvement in leber hereditary optic neuropathy: an open-labeled, nonrandomized multicenter trial of topical brimonidine purite. Am J Ophthalmol. 2005;140:407–15.
    1. Newman NJ, Lott MT, Wallace DC. The clinical characteristics of pedigrees of Leber's hereditary optic neuropathy with the 11 778 mutation. American Journal of Ophthalmology. 1991;111:750–62.
    1. Nikoskelainen EK, Huoponen K, Juvonen V, Lamminen T, Nummelin K, Savontaus M-L. Ophthalmologic findings in Leber hereditary optic neuropathy, with special reference to mtDNA mutations. Ophthalmology. 1996;103:540–14.
    1. Riordan-Eva P, Sanders MD, Govan GG, Sweeney MG, Da Costa J, Harding AE. The clinical features of Leber's hereditary optic neuropathy defined by the presence of a pathogenic mitochondrial DNA mutation. Brain. 1995;118:319–37.
    1. Schaefer AM, Taylor RW, Turnbull DM, Chinnery PF. The epidemiology of mitochondrial disorders-past, present and future. Biochim Biophys Acta. 2004;1659:115–20.
    1. Subei AM, Eggenberger ER. Optical coherence tomography: another useful tool in a neuro-ophthalmologist's armamentarium. Curr Opin Ophthalmol. 2009;20:462–6.
    1. van den Bosch M, Wall M. Visual acuity scored by the letter-by-letter or probit methods has lower retest variability than the line assignment method. Eye. 1997;11:411–17.
    1. Ventura DF, Gualtieri M, Oliveira AG, Costa MF, Quiros P, Sadun F, et al. Male prevalence of acquired color vision defects in asymptomatic carriers of Leber's hereditary optic neuropathy. Invest Ophthalmol Vis Sci. 2007;48:2362–70.
    1. Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York: Springer; 2000.
    1. Zanna C, Ghelli A, Porcelli AM, Martinuzzi A, Carelli V, Rugolo M. Caspase-independent death of Leber's hereditary optic neuropathy cybrids is driven by energetic failure and mediated by AIF and Endonuclease G. Apoptosis. 2005;10:997–1007.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit